Bio-Pharm

Celltrion “Remsima SC captures 22% market share in Europe”

Celltrion’s Remsima SC is solidifying its position as a leading autoimmune disease treatment in Europe. On May 28, Celltrion announced that its subcutaneous (SC) formulation of infliximab, “Remsima SC,” had…

Cheon Okhyeon

2025-05-28

Samsung Biologics to Spin Off Biosimilar Unit, Launching a Two-Track Strategy

Samsung Group’s biopharmaceutical business is being reorganized into two separate tracks: CDMO (Contract Development and Manufacturing Organization) and biosimilars. Samsung Biologics plans to conduct a vertical spin-off, separating its subsidiary…

Cheon Okhyeon

2025-05-22

SK Bioscience Prevails Over Pfizer in Patent Dispute

SK Bioscience has secured a decisive victory in a long-standing patent dispute with Pfizer, clearing the path for the company to accelerate its global pneumococcal vaccine business, including exports of…

Cheon Okhyeon

2025-05-21

Weak Earnings, Silent Pipeline: Chong Kun Dang Pharmaceutical Bets on CAR-T and ADC for Comeback

Chong Kun Dang Pharmaceutical Corp., once in the spotlight for a blockbuster licensing deal worth KRW 1.7 trillion ($1.25 billion) at the end of 2023, is now facing a dual…

Cheon Okhyeon

2025-05-20

GC Biopharma Secures FDA Approval for All 6 U.S. Plasma Centers…Sets Stage for ALYGLO Growth

GC Biopharma announced on the 14th that all six of its plasma centers in the United States have received approval from the U.S. Food and Drug Administration (FDA), establishing a…

Cheon Okhyeon

2025-05-14

Hugel posts record Q1 operating profit of KRW39 billion

Hugel, a global total medical aesthetics company, posted its highest-ever first-quarter performance, fueled by robust sales across all product lines. The company announced on May 8 that its consolidated revenue…

Cheon Okhyeon

2025-05-08

Samsung Bioepis Wins U.S. Injunction Case Over Stelara Biosimilar

Samsung Bioepis has cleared a key legal hurdle in the U.S. market for its autoimmune disease biosimilar Pyzchiva, following a court ruling that dismissed an injunction request by Johnson &…

Cheon Okhyeon

2025-04-30

SK Biopharm Targets KRW 700 Billion in Annual Sales on Strong Epilepsy Drug Growth

SK Biopharm has set its sights on surpassing KRW 700 billion (approximately $515 million) in annual sales this year, driven by strong growth of its epilepsy drug, cenobamate (U.S. brand…

Cheon Okhyeon

2025-04-29